LOAME
BMRN icon

Lombard Odier Asset Management (Europe)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lombard Odier Asset Management (Europe)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,313
Closed -$215K – 416
2017
Q3 		$215K Hold
2,313
– – 0.01% 400
2017
Q2 		$210K Hold
2,313
– – 0.01% 395
2017
Q1 		$203K Buy
+2,313
New +$206K 0.01% 378

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lombard Odier Asset Management (Europe)'s BMRN Position: Q4 2017 in Review

Lombard Odier Asset Management (Europe) sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 2,313 shares — an estimated $215K sold.

Lombard Odier Asset Management (Europe) first reported a position in BMRN in Q1 2017 and held it in 3 quarters. The position peaked at $215K in Q3 2017. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

  • Lombard Odier Asset Management (Europe) reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Lombard Odier Asset Management (Europe) sold 2,313 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $215K.
  • Lombard Odier Asset Management (Europe) first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 3 quarters.
  • Lombard Odier Asset Management (Europe)'s BioMarin Pharmaceuticals position peaked at $215K in Q3 2017.
  • 438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Lombard Odier Asset Management (Europe)'s 13F filing for Q4 2017, filed 13 Feb 2018.